Poussot to take over as Wyeth CEO

Share this article:

Wyeth will promote its No. 2 executive, Bernard Poussot, to CEO effective Jan.1 under a planned succession, the drugmaker said.

Poussot will succeed current CEO Robert Essner, who will become non-executive chairman of the board during a transition period beginning in the new year.

Poussot has served as Wyeth's president and vice chairman since April 2006. In January he added the role of chief operating officer.

Essner has worked at Wyeth since 1989 and has been CEO since May 2001.
 

Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.